Figure 6
From: Tumor promoting effects of CD95 signaling in chemoresistant cells
Analysis of EMT markers on HT29 and RHT29 xenografts. (A1) Differential basal expression of some transcription factors related to the EMT process and (A2) markers of epithelial and mesenchymal phenotype were determined by qPCR in tumor xenografts derived from the HT29 and RHT29 cell lines. (B1) The effects of oxaliplatin in the gene expression of those transcription factors and (B2) EMT markers were also analyzed in xenografted tumors treated with oxaliplatin (i.p. 10 mg/kg) once per week during 27 days and in this case the results are shown as fold induction versus non-treated tumors. Results represent the mean ± SEM for 6 xenografts per group. Values that are significantly different between (A) groups or between (B) non-treated and treated groups by ANOVA's analysis are indicated by *p < 0.05, **p < 0.01, ***p < 0.001.